n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)
Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript

Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript

Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript

Santarus Announces Supportive Top-Line Results From Budesonide MMX Extended Use Study

Santarus Announces Supportive Top-Line Results From Budesonide MMX Extended Use Study

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with...

Santarus To Present At September Investment Conferences

Santarus To Present At September Investment Conferences

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products

Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products

Santarus, Inc. (NASDAQ:SNTS) and Depomed, Inc.

Santarus To Present At The 2011 Wedbush Life Sciences: Management Access Conference

Santarus To Present At The 2011 Wedbush Life Sciences: Management Access Conference

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Pharming Announce Special Protocol Assessment (SPA) Agreement With FDA For RHUCIN Phase III Clinical Study

Santarus And Pharming Announce Special Protocol Assessment (SPA) Agreement With FDA For RHUCIN Phase III Clinical Study

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that they have reached agreement with the U.

Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript

Santarus Reports Second Quarter 2011 Financial Results

Santarus Reports Second Quarter 2011 Financial Results

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2011.

Santarus To Hold Second Quarter 2011 Financial Results Conference Call On August 3

Santarus To Hold Second Quarter 2011 Financial Results Conference Call On August 3

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it will release second quarter 2011 financial results after market close on Wednesday, August 3, 2011.

Santarus Appoints Wendell Wierenga Executive Vice President, Research And Development

Santarus Appoints Wendell Wierenga Executive Vice President, Research And Development

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, announces that Wendell Wierenga, Ph.

Santarus To Present At The Wells Fargo Securities 2011 Healthcare Conference

Santarus To Present At The Wells Fargo Securities 2011 Healthcare Conference

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus Announces Presentation Of RHUCIN Clinical Data At 7th C1 Inhibitor Deficiency Workshop

Santarus Announces Presentation Of RHUCIN Clinical Data At 7th C1 Inhibitor Deficiency Workshop

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN ® (recombinant...

Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript

Santarus Reports First Quarter 2011 Financial Results

Santarus Reports First Quarter 2011 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2011.

Santarus Announces Oral Presentations Of Budesonide MMX Phase III Data At Digestive Disease Week Meeting

Santarus Announces Oral Presentations Of Budesonide MMX Phase III Data At Digestive Disease Week Meeting

Santarus, Inc. (NASDAQ: SNTS) today announced that the budesonide MMX ® Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week (DDW) Meeting being held at McCormick Place ...

Santarus To Hold First Quarter 2011 Financial Results Conference Call On May 4

Santarus To Hold First Quarter 2011 Financial Results Conference Call On May 4

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release first quarter 2011 financial results after market close on Wednesday, May 4, 2011.

Santarus And Pharming Announce RHUCIN Poster At American Academy Of Allergy, Asthma & Immunology 2011 Annual Meeting

Santarus And Pharming Announce RHUCIN Poster At American Academy Of Allergy, Asthma & Immunology 2011 Annual Meeting

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ:SNTS) and biotech company Pharming Group NV (NYSE Euronext:PHARM) today announced new data on 62 patients with Hereditary Angioedema (HAE) who received repeat...

Santarus Initiates Phase I Clinical Study With SAN-300

Santarus Initiates Phase I Clinical Study With SAN-300

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

Santarus Inc. Stock Downgraded (SNTS)

Santarus Inc. Stock Downgraded (SNTS)

Santarus (Nasdaq:SNTS) has been downgraded by TheStreet Ratings from from a hold to sell.

SuperGen - Upgrades & Downgrades

SuperGen - Upgrades & Downgrades

TheStreet Ratings released rating changes on 21 U.S. common stocks for March 3, 2011. 12 stocks were upgraded and nine stocks were downgraded by our stock model.

Santarus Management Discusses Q4 2010 Results - Earnings Call Transcript

Santarus Management Discusses Q4 2010 Results - Earnings Call Transcript

Santarus Management Discusses Q4 2010 Results - Earnings Call Transcript

Santarus Reports Fourth Quarter And Full Year 2010 Financial Results

Santarus Reports Fourth Quarter And Full Year 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter and full year ended December 31, 2010.

Santarus To Present At March Investment Conferences

Santarus To Present At March Investment Conferences

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Pharming Announce Receipt Of FDA Refusal To File Letter For RHUCIN Biologics License Application

Santarus And Pharming Announce Receipt Of FDA Refusal To File Letter For RHUCIN Biologics License Application

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ:SNTS) and biotech company Pharming Group NV (NYSE Euronext:PHARM) today announced the receipt of a “refusal to file” letter from the U.

Santarus To Hold Fourth Quarter And Full Year 2010 Financial Results Conference Call On March 3

Santarus To Hold Fourth Quarter And Full Year 2010 Financial Results Conference Call On March 3

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release fourth quarter and full year 2010 financial results after market close on Thursday, March 3, 2011.

Santarus And Pharming Announce Initiation Of Phase IIIb Clinical Study With RHUCIN In Acute Hereditary Angioedema

Santarus And Pharming Announce Initiation Of Phase IIIb Clinical Study With RHUCIN In Acute Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, ...

Santarus To Present At The 13th Annual Bio CEO & Investor Conference

Santarus To Present At The 13th Annual Bio CEO & Investor Conference

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets

Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets

Santarus, Inc. (NASDAQ: SNTS) and Depomed, Inc.

Savient Pharmaceuticals: Premarket Trading

Savient Pharmaceuticals: Premarket Trading

Savient Pharmaceuticals president Paul Hamelin will continue to lead the company until it hires a new CEO.

Beazer, Sears, KBR Are Big Market Movers

Beazer, Sears, KBR Are Big Market Movers

Beazer, Sears, KBR, Rare Element Resources, Hecla are big market movers Tuesday